Marinus Pharmaceuticals (MRNS) shares plunged nearly 82% in recent Thursday trading after the company said its phase 3 trial of oral ganaxolone failed to meet its main goal and announced plans to reduce costs and explore alternatives for the business.
Marinus was studying the drug as a treatment for seizures associated with tuberous sclerosis complex in children and adults. The trial failed to achieve "statistical significance" on its primary endpoint of percent change in 28-day frequency of tuberous sclerosis complex-associated seizures, the drugmaker said.
Marinus said it would no longer be developing ganaxolone and would take steps to save costs, including a workforce reduction.
The company also said it has hired Barclays to assist in reviewing its strategic alternatives.
Price: 0.31, Change: -1.38, Percent Change: -81.89
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。